Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance
BACKGROUND: Sickle cell trait is the carrier state for sickle cell disease and occurs in 1 in 13 births in Black and African American families. Individuals with sickle cell trait are permitted to serve in the military. Some research studies have shown that individuals with sickle cell trait may be a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | AJOG Global Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666577825000589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849682776789352448 |
|---|---|
| author | Angela K. Phillips, PhD, APRN Candy Wilson, PhD, APRN, FAAN Anwar E. Ahmed, PhD Arun Shet, MD, PhD Margaret Bevans, PhD, RN, FAAN |
| author_facet | Angela K. Phillips, PhD, APRN Candy Wilson, PhD, APRN, FAAN Anwar E. Ahmed, PhD Arun Shet, MD, PhD Margaret Bevans, PhD, RN, FAAN |
| author_sort | Angela K. Phillips, PhD, APRN |
| collection | DOAJ |
| description | BACKGROUND: Sickle cell trait is the carrier state for sickle cell disease and occurs in 1 in 13 births in Black and African American families. Individuals with sickle cell trait are permitted to serve in the military. Some research studies have shown that individuals with sickle cell trait may be at increased risk for thromboembolic events. Contraceptive use, specifically combined hormonal contraceptives containing both estrogen and progesterone, has been linked to an increased risk of thromboembolic events. No research has been done to determine if there is an increased risk of venous thromboembolism in a population of females with sickle cell trait who do or do not take combined hormonal contraceptives. OBJECTIVE: To determine if women with sickle cell trait who use combined hormonal contraceptives are at higher risk for venous thromboembolism compared with females with sickle cell trait who do not use combined hormonal contraceptives. Given the increased risk of venous thromboembolism in sickle cell trait individuals in the general population, we hypothesized that females with sickle cell trait exposed to combined hormonal contraceptives would experience higher venous thromboembolism rates than unexposed females with sickle cell trait. STUDY DESIGN: Population-based retrospective cohort study of females with sickle cell trait identified from the Military Data Repository to evaluate venous thromboembolism after exposure to combined hormonal contraceptives or without exposure to combined hormonal contraceptives. RESULTS: There were 15,440 unique females aged 18–44 years between 2005 and 2021 who had a diagnosis of sickle cell trait. Approximately 40% of females had an International Classification of Diseases code consistent with a prescription of a combined hormonal contraceptive. Thirty-three (0.2%) of the 15,440 females with sickle cell trait had experienced venous thromboembolism of any type. There was no difference in the prevalence of venous thromboembolism by combined hormonal contraceptive use (yes [0.18%] vs no [0.24%]; P=.454). Being older, married, nonactive-duty military status, smoking, and having a diagnosis of hypertension were associated with a higher prevalence of venous thromboembolism. CONCLUSION: Although there was a small number of venous thromboembolism events, the findings of this study suggest that the use of combined hormonal contraceptives in females with sickle cell trait is not associated with a detectable signal for increased venous thromboembolism risk as an outcome. Given the potential clinical benefit of combined hormonal contraceptives in pregnancy prevention and menstrual regulation in females, the concerns about combined hormonal contraceptive-associated venous thromboembolism in this population with sickle cell trait seem to be minimal. |
| format | Article |
| id | doaj-art-04b7b0aa30974906a4e33dee23f1f235 |
| institution | DOAJ |
| issn | 2666-5778 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | AJOG Global Reports |
| spelling | doaj-art-04b7b0aa30974906a4e33dee23f1f2352025-08-20T03:24:04ZengElsevierAJOG Global Reports2666-57782025-05-015210049710.1016/j.xagr.2025.100497Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a GlanceAngela K. Phillips, PhD, APRN0Candy Wilson, PhD, APRN, FAAN1Anwar E. Ahmed, PhD2Arun Shet, MD, PhD3Margaret Bevans, PhD, RN, FAAN4Operational Clinical Quality, Air Force Medical Command, Falls Church, VA (Philips); Corresponding author: Angela K. Phillips, PhD, APRN.Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton, FL (Wilson)Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD (Ahmed)National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (Shet and Bevans).National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (Shet and Bevans).BACKGROUND: Sickle cell trait is the carrier state for sickle cell disease and occurs in 1 in 13 births in Black and African American families. Individuals with sickle cell trait are permitted to serve in the military. Some research studies have shown that individuals with sickle cell trait may be at increased risk for thromboembolic events. Contraceptive use, specifically combined hormonal contraceptives containing both estrogen and progesterone, has been linked to an increased risk of thromboembolic events. No research has been done to determine if there is an increased risk of venous thromboembolism in a population of females with sickle cell trait who do or do not take combined hormonal contraceptives. OBJECTIVE: To determine if women with sickle cell trait who use combined hormonal contraceptives are at higher risk for venous thromboembolism compared with females with sickle cell trait who do not use combined hormonal contraceptives. Given the increased risk of venous thromboembolism in sickle cell trait individuals in the general population, we hypothesized that females with sickle cell trait exposed to combined hormonal contraceptives would experience higher venous thromboembolism rates than unexposed females with sickle cell trait. STUDY DESIGN: Population-based retrospective cohort study of females with sickle cell trait identified from the Military Data Repository to evaluate venous thromboembolism after exposure to combined hormonal contraceptives or without exposure to combined hormonal contraceptives. RESULTS: There were 15,440 unique females aged 18–44 years between 2005 and 2021 who had a diagnosis of sickle cell trait. Approximately 40% of females had an International Classification of Diseases code consistent with a prescription of a combined hormonal contraceptive. Thirty-three (0.2%) of the 15,440 females with sickle cell trait had experienced venous thromboembolism of any type. There was no difference in the prevalence of venous thromboembolism by combined hormonal contraceptive use (yes [0.18%] vs no [0.24%]; P=.454). Being older, married, nonactive-duty military status, smoking, and having a diagnosis of hypertension were associated with a higher prevalence of venous thromboembolism. CONCLUSION: Although there was a small number of venous thromboembolism events, the findings of this study suggest that the use of combined hormonal contraceptives in females with sickle cell trait is not associated with a detectable signal for increased venous thromboembolism risk as an outcome. Given the potential clinical benefit of combined hormonal contraceptives in pregnancy prevention and menstrual regulation in females, the concerns about combined hormonal contraceptive-associated venous thromboembolism in this population with sickle cell trait seem to be minimal.http://www.sciencedirect.com/science/article/pii/S2666577825000589combined hormonal contraceptiveslatent class analysispopulation-based researchsecondary data analysis |
| spellingShingle | Angela K. Phillips, PhD, APRN Candy Wilson, PhD, APRN, FAAN Anwar E. Ahmed, PhD Arun Shet, MD, PhD Margaret Bevans, PhD, RN, FAAN Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance AJOG Global Reports combined hormonal contraceptives latent class analysis population-based research secondary data analysis |
| title | Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance |
| title_full | Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance |
| title_fullStr | Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance |
| title_full_unstemmed | Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance |
| title_short | Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance |
| title_sort | venous thromboembolism with contraceptive use in females with sickle cell traitajog global reports at a glance |
| topic | combined hormonal contraceptives latent class analysis population-based research secondary data analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2666577825000589 |
| work_keys_str_mv | AT angelakphillipsphdaprn venousthromboembolismwithcontraceptiveuseinfemaleswithsicklecelltraitajogglobalreportsataglance AT candywilsonphdaprnfaan venousthromboembolismwithcontraceptiveuseinfemaleswithsicklecelltraitajogglobalreportsataglance AT anwareahmedphd venousthromboembolismwithcontraceptiveuseinfemaleswithsicklecelltraitajogglobalreportsataglance AT arunshetmdphd venousthromboembolismwithcontraceptiveuseinfemaleswithsicklecelltraitajogglobalreportsataglance AT margaretbevansphdrnfaan venousthromboembolismwithcontraceptiveuseinfemaleswithsicklecelltraitajogglobalreportsataglance |